Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

B. C. Creelan; T. Yeh; S. W. Kim; N. Nogami; D. W. Kim; L. Q. Chow; S. Kanda; R. Taylor; W. Tang; M. Tang; H. K. Angell; M. P. Roudier; M. Marotti; D. L. Gibbons

doi:10.1093/annonc/mdz067.001

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

B. C. Creelan, T. Yeh, S. W. Kim, N. Nogami, D. W. Kim, L. Q. Chow, S. Kanda, R. Taylor, W. Tang, M. Tang, H. K. Angell, M. P. Roudier, M. Marotti, D. L. Gibbons

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	ii31-ii32
Journal	Annals of Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz067.001
State	Published - Apr 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz067.001

Cite this

Creelan, B. C., Yeh, T., Kim, S. W., Nogami, N., Kim, D. W., Chow, L. Q., Kanda, S., Taylor, R., Tang, W., Tang, M., Angell, H. K., Roudier, M. P., Marotti, M., & Gibbons, D. L. (2019). Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations. Annals of Oncology, 30, ii31-ii32. https://doi.org/10.1093/annonc/mdz067.001

Creelan, BC, Yeh, T, Kim, SW, Nogami, N, Kim, DW, Chow, LQ, Kanda, S, Taylor, R, Tang, W, Tang, M, Angell, HK, Roudier, MP, Marotti, M & Gibbons, DL 2019, 'Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations', Annals of Oncology, vol. 30, pp. ii31-ii32. https://doi.org/10.1093/annonc/mdz067.001

@article{daf6708c14d049d38d69d12a890d0134,

title = "Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations",

author = "Creelan, {B. C.} and T. Yeh and Kim, {S. W.} and N. Nogami and Kim, {D. W.} and Chow, {L. Q.} and S. Kanda and R. Taylor and W. Tang and M. Tang and Angell, {H. K.} and Roudier, {M. P.} and M. Marotti and Gibbons, {D. L.}",

year = "2019",

month = apr,

doi = "10.1093/annonc/mdz067.001",

language = "English (US)",

volume = "30",

pages = "ii31--ii32",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

AU - Creelan, B. C.

AU - Yeh, T.

AU - Kim, S. W.

AU - Nogami, N.

AU - Kim, D. W.

AU - Chow, L. Q.

AU - Kanda, S.

AU - Taylor, R.

AU - Tang, W.

AU - Tang, M.

AU - Angell, H. K.

AU - Roudier, M. P.

AU - Marotti, M.

AU - Gibbons, D. L.

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85073442037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073442037&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz067.001

DO - 10.1093/annonc/mdz067.001

M3 - Article

C2 - 32131217

SN - 0923-7534

VL - 30

SP - ii31-ii32

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this